IPCA Laboratories Limited
IPCA Laboratories Limited (IPCALAB) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
ipca.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,034 Cr | 2,053 Cr | 2,033 Cr | 2,093 Cr | 2,355 Cr | 2,245 Cr | 2,247 Cr | 2,309 Cr | 2,557 Cr | 2,393 Cr | 2,388 Cr | 2,788 Cr |
| Operating expenses (approx.) | 1,713 Cr | 1,722 Cr | 1,711 Cr | 1,700 Cr | 1,913 Cr | 1,782 Cr | 1,818 Cr | 1,892 Cr | 2,012 Cr | 1,859 Cr | 1,905 Cr | 2,119 Cr |
| EBITDA | 321 Cr | 331 Cr | 322 Cr | 393 Cr | 441 Cr | 463 Cr | 429 Cr | 416 Cr | 545 Cr | 533 Cr | 484 Cr | 670 Cr |
| OPM % | 15.8% | 16.1% | 15.8% | 18.8% | 18.7% | 20.6% | 19.1% | 18.0% | 21.3% | 22.3% | 20.3% | 24.0% |
| Other income | 39 Cr | 22 Cr | 19 Cr | 21 Cr | 26 Cr | 20 Cr | 26 Cr | 33 Cr | 28 Cr | 20 Cr | 94 Cr | 25 Cr |
| Interest | 44 Cr | 33 Cr | 29 Cr | 24 Cr | 23 Cr | 17 Cr | 22 Cr | 19 Cr | 20 Cr | 18 Cr | 20 Cr | 12 Cr |
| Depreciation | 90 Cr | 100 Cr | 98 Cr | 99 Cr | 100 Cr | 98 Cr | 100 Cr | 100 Cr | 103 Cr | 108 Cr | 107 Cr | 111 Cr |
| Profit before tax | 224 Cr | 287 Cr | 75 Cr | 291 Cr | 345 Cr | 367 Cr | 126 Cr | 329 Cr | 389 Cr | 446 Cr | 402 Cr | 574 Cr |
| Tax % | 39.2% | 23.1% | 98.2% | 31.5% | 28.8% | 24.7% | 49.3% | 29.2% | 27.8% | 18.4% | 23.7% | 26.0% |
| Net profit | 136 Cr | 221 Cr | 1 Cr | 199 Cr | 246 Cr | 276 Cr | 64 Cr | 233 Cr | 281 Cr | 364 Cr | 307 Cr | 424 Cr |
| EPS (₹) | ₹5.72 | ₹7.09 | ₹2.35 | ₹7.58 | ₹9.05 | ₹9.78 | ₹2.67 | ₹9.19 | ₹11.14 | ₹12.86 | ₹11.79 | ₹15.84 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,773 Cr | 4,649 Cr | 5,420 Cr | 5,830 Cr | 6,244 Cr | 7,705 Cr | 8,940 Cr | 9,646 Cr | Sign in for TTM |
| Operating expenses (approx.) | 3,081 Cr | 3,742 Cr | 3,876 Cr | 4,521 Cr | 5,318 Cr | 6,384 Cr | 7,213 Cr | 7,668 Cr | Sign in for TTM |
| EBITDA | 692 Cr | 907 Cr | 1,544 Cr | 1,309 Cr | 927 Cr | 1,321 Cr | 1,726 Cr | 1,979 Cr | Sign in for TTM |
| OPM % | 18.3% | 19.5% | 28.5% | 22.5% | 14.8% | 17.1% | 19.3% | 20.5% | Sign in for TTM |
| Other income | 58 Cr | 67 Cr | 63 Cr | 67 Cr | 126 Cr | 125 Cr | 93 Cr | 174 Cr | Sign in for TTM |
| Interest | 19 Cr | 17 Cr | 9 Cr | 8 Cr | 46 Cr | 138 Cr | 85 Cr | 76 Cr | Sign in for TTM |
| Depreciation | 182 Cr | 211 Cr | 209 Cr | 232 Cr | 262 Cr | 357 Cr | 398 Cr | 418 Cr | Sign in for TTM |
| Profit before tax | 546 Cr | 739 Cr | 1,381 Cr | 1,114 Cr | 732 Cr | 836 Cr | 1,129 Cr | 1,565 Cr | Sign in for TTM |
| Tax % | 19.1% | 18.3% | 17.4% | 20.1% | 34.6% | 37.5% | 30.4% | 24.4% | Sign in for TTM |
| Net profit | 442 Cr | 604 Cr | 1,141 Cr | 890 Cr | 479 Cr | 523 Cr | 785 Cr | 1,184 Cr | Sign in for TTM |
| EPS (₹) | ₹35.01 | ₹47.77 | ₹90.11 | ₹34.85 | ₹18.58 | ₹21.57 | ₹29.08 | ₹44.98 | Sign in for TTM |
| Dividend payout % | — | — | — | 11.4% | 21.2% | 9.7% | 12.9% | 4.4% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr |
| Reserves | 3,097 Cr | 3,602 Cr | 4,676 Cr | 5,467 Cr | 5,817 Cr | 6,307 Cr | 6,923 Cr | 8,038 Cr |
| Borrowings | 351 Cr | 414 Cr | 186 Cr | 791 Cr | 1,458 Cr | 1,388 Cr | 1,302 Cr | 704 Cr |
| Other liabilities | 1,062 Cr | 1,205 Cr | 1,166 Cr | 1,279 Cr | 1,254 Cr | 1,987 Cr | 2,071 Cr | 2,142 Cr |
| Total liabilities | 4,551 Cr | 5,260 Cr | 6,068 Cr | 7,639 Cr | 8,626 Cr | 11,101 Cr | 11,761 Cr | 12,370 Cr |
| Fixed assets (net) | 1,746 Cr | 1,922 Cr | 1,963 Cr | 2,209 Cr | 2,572 Cr | 4,340 Cr | 4,069 Cr | 4,441 Cr |
| CWIP | 36 Cr | 71 Cr | 184 Cr | 294 Cr | 122 Cr | 324 Cr | 616 Cr | 762 Cr |
| Investments | 120 Cr | 310 Cr | 505 Cr | 989 Cr | 626 Cr | 862 Cr | 980 Cr | 844 Cr |
| Loans & advances | 3 Cr | 3 Cr | 2 Cr | 10 Cr | 3 Cr | 9 Cr | 43 Cr | 50 Cr |
| Inventories | 1,073 Cr | 1,323 Cr | 1,595 Cr | 1,858 Cr | 1,743 Cr | 2,471 Cr | 2,560 Cr | 2,731 Cr |
| Trade receivables | 682 Cr | 895 Cr | 812 Cr | 911 Cr | 989 Cr | 1,687 Cr | 1,874 Cr | 2,014 Cr |
| Cash & bank | 281 Cr | 58 Cr | 166 Cr | 275 Cr | 1,258 Cr | 209 Cr | 167 Cr | 437 Cr |
| Other assets | 610 Cr | 677 Cr | 842 Cr | 1,093 Cr | 1,312 Cr | 1,200 Cr | 1,452 Cr | 1,092 Cr |
| Total assets | 4,551 Cr | 5,260 Cr | 6,068 Cr | 7,639 Cr | 8,626 Cr | 11,101 Cr | 11,761 Cr | 12,370 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 856 Cr | 806 Cr | 945 Cr | 1,321 Cr | 1,142 Cr |
| Cash from investing | — | — | — | -855 Cr | -725 Cr | -1,292 Cr | -869 Cr | -247 Cr |
| Cash from financing | — | — | — | 427 Cr | 507 Cr | -553 Cr | -283 Cr | -754 Cr |
| Net cash flow | — | — | — | 428 Cr | 588 Cr | -900 Cr | 169 Cr | 142 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 377 Cr | 311 Cr | 533 Cr | 546 Cr | 490 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 18.1% | 20.8% | 29.6% | 20.4% | 10.6% | 10.7% | 12.5% | 16.0% |
| ROE % | 14.2% | 16.7% | 24.2% | 16.1% | 8.0% | 7.1% | 8.8% | 12.0% |
| Debtor days | 66 | 70 | 55 | 57 | 58 | 80 | 76 | 76 |
| Inventory days | 353 | 331 | 363 | 406 | 371 | 407 | 409 | 424 |
| Days payable | 173 | 152 | 152 | 122 | 112 | 128 | 135 | 146 |
| Cash conversion cycle | 246 | 249 | 266 | 341 | 317 | 359 | 350 | 354 |
| Debt / equity | 0.11 | 0.00 | 0.04 | 0.14 | 0.25 | 0.22 | 0.19 | 0.09 |
| Current ratio | 2.17 | 2.15 | 3.03 | 3.03 | 2.87 | 2.35 | 2.50 | 2.76 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.89 | 0.66 | 0.13 |
Compare with peers
Loading peers…